START to open Phase I oncology unit in China

By Nick Taylor

- Last updated on GMT

Related tags: Phase, Clinical trial

START is opening an oncology-focused Phase I unit in China to meet demand for early-stage cancer trials in the growth market.

Establishing the 5,000 sq ft oncology unit in Shanghai, China expands South Texas Accelerated Research Therapeutics’ (START) Phase I network into Asia. The site allows multinational sponsors to tap into China, supports local research and improves access to experimental drugs.

START is opening the unit, a joint venture with China-based Cenova Ventures, on the fourth floor of the Fudan University Shanghai Cancer Center (FUSCC). An estimated 600,000 patients visit FUSCC each year, giving sponsors access to a significant number of potential trial participants.

We expect to enrol our first patient in July​”, said Gina Mangold, chief operating officer at START. Before then START will train staff, renovate clinical space, purchase equipment and secure sponsors. START hopes to have a 50/50 split between local and multinational pharma sponsors.

When operational the site will house 10 transfusion chairs for use in conducting Phase I trials. Initially 11 people will work at the unit but START plans to hire a further 18 employees within two years of opening.

International oncology expansion

The Shanghai site follows the launch of START Phase I units in San Antonio, Texas and Madrid, Spain. START plans to open more Phase I units, Anthony Tolcher, clinical director at company, told Outsourcing-Pharma, but a specific timeline or target geographies are yet to be decided.

When researchers are ending the day in one START location, our colleagues will be starting their day and will pick up right where we left off​”, said Tolcher in a press statement.

Phase I in China

The site will boost Phase I oncology capabilities, an underdeveloped area at FUSCC and throughout China, to further its drug development aspirations in an important, expanding therapeutic area.

It is important for us to upgrade our capabilities in conducting early phase and first-time-in-human (FTIH) clinical studies​”, said Jin Li, director of the oncology unit at FUSCC. ​Most previous trials at FUSCC have been Phase II and III.

FUSCC has limited Phase I experience but has a heritage in clinical trials and is keen to expand capabilities. It was among the first sites to receive a Chinese State Food and Drug Administration (SFDA) experimental drug test license and is now moving to the forefront of Phase I oncology.

For us, we can learn the American experience in drug development, improve our system in drug tests and increase our center’s impact in the world. We are excited about this collaboration​”, said Guoliang Jiang, president of FUSCC.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more